Morniflumate is a non-steroidal anti-inflammatory drug and represent as a beta-morpholinoethyl ester of niflumic acid, which is rapidly hydrolyzed in the plasma, releasing the free acidic form, the molecule responsible for the pharmacological effects. It was shown, that morniflumate was effective in the treatment of chronic recurring bronchitis and inhibited cyclooxygenase-1, 2 (COX-1, 2). Morniflumate has a 30-year history of clinical use, particularly for the treatment of pain associated with pediatric ear-nose-throat (ENT) infection. In addition, it appears to be a valid and well-tolerated alternative to other NSAIDs, or to antibiotics, for the treatment of pain and other symptoms of soft tissue inflammation.

Acreozast is an orally active antiallergic agent, which has anti-inflammatory activity. It was undergoing phase II clinical trials in Japan for the following condition: Asthma and Atopic dermatitis. Toyobo discontinued the development of acreozast in 1996.

Balazipone (OR 1364), an anti-inflammatory drug that was participated in clinical trials Phase-I for Crohn's disease in Finland.

Dimethyl phthalate, an organic compound, is used as repellents. This compound is a pollutant that is very harmful to organisms due to its mutagenicity, teratogenicity and carcinogenicity. It was discovered, that dimethyl phthalate could alter the biological function of the one of the most important bacteria in the environment, P. fluorescens.

Antrafenine (SL 73033 or 2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl 2-[[7-(trifluoromethyl)-4-quinolinyl]amino]benzoate) showed marked analgesic activity, long duration of action, and excellent tolerance in pharmacological and toxicological studies. Antrafenine exerts anti-inflammatory effects. It has been studied in the treatment of osteoarthritis.

Broperamole has been studied as an anti-inflammatory agent.

Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects. Although its mechanism of action is incompletely defined, amsacrine inhibits DNA synthesis by binding to and intercalating with DNA. Amsacrine also inhibits topoisomerase II activity and may exert an effect on cell membranes. This agent also possesses immunosuppressive and antiviral properties. While amsacrine is not cell cycle phase-specific, cytotoxicity is maximal during the G2 and S phases.

AMFLUTIZOLE is a xanthine oxidase inhibitor used for the treatment of gout.

Nilvadipine (NIVADIL®) is a L-type calcium channel blocker for treatment of hypertension. It inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Tolciclate [O-(1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl)-m,N-dimethylthiocarbanilate] is an antimycotic agent with specific activity on dermatophytes. In vitro it is as active as tolnaftate, but shows greater liposolubility, which might be important for in vivo activity. When applied topically for 10 days to guinea pigs infected acutely with Trichophyton mentagrophytes (synonymous with T. asteroides), it is about three times more active than tolnaftate. Inhibition by tolciclate of sterol synthesis through blocking the step of squalene epoxidation in a fungal sterol biosynthetic pathway may be primarily involved in the antifungal action of the drug.